SLC30A9

Across TCGA pan-cancer cohorts, SLC30A9 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC30A9 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SLC30A9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC30A9 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

HNSC, SKCM, and LUSC are the cancer types where SLC30A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.156	0.743	.001	42	view →
SKCM	OS	Median	III,IV	0.267	0.701	.017	7	view →
LUSC	DFS	Median	II,III,IV	1.000	0.343	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC30A9–HNSC (OS)

Open the HNSC breakdown →